Download PDF
Thromb Haemost 1998; 80(04): 686-691
DOI: 10.1055/s-0037-1615442
Rapid Communication
Schattauer GmbH

Thrombin and Human Plasma Kallikrein Inhibition during Simulated Extracorporeal Circulation Block Platelet and Neutrophil Activation

Yanina T. Wachtfogel
1   From the Sol Sherry Thrombosis Research Center and the Hematology Division, Department of Medicine, Temple University School of Medicine, Philadelphia, PA, USA
,
Charles Kettner
2   Du Pont Merck Pharmaceutical Company, Wilmington, DE, USA
,
C. Erik Hack
3   Central Laboratory of the Netherlands Red Cross, Blood Transfusion Service and Laboratory for Experimental and Clinical Immunology, University of Amsterdam, Amsterdam, The Netherlands
,
Jan H. Nuijens
4   Gene Pharming Europe BV, Leiden, The Netherlands
,
Thomas M. Reilly
2   Du Pont Merck Pharmaceutical Company, Wilmington, DE, USA
,
Robert M. Knabb
2   Du Pont Merck Pharmaceutical Company, Wilmington, DE, USA
,
Umberto Kucich
5   Research Division, Department of Medicine, The Graduate Hospital, Philadelphia, PA, USA
,
Stefan Niewiarowski
1   From the Sol Sherry Thrombosis Research Center and the Hematology Division, Department of Medicine, Temple University School of Medicine, Philadelphia, PA, USA
,
L. Henry Edmunds Jr.
6   Division of Cardiothoracic Surgery, Harrison Department of Surgery, Hospital of the University of Pennsylvania, Philadelphia, PA, USA
,
Robert W. Colman
1   From the Sol Sherry Thrombosis Research Center and the Hematology Division, Department of Medicine, Temple University School of Medicine, Philadelphia, PA, USA
› Author Affiliations
Further Information

Publication History

Received 30 May 1998

Accepted after resubmission 17 June 1998

Publication Date:
08 December 2017 (online)

    Permissions and Reprints

Summary

Cardiopulmonary bypass causes hemorrhagic complications, and initiates a chemical and cellular inflammatory response. Contact of blood with synthetic surfaces leads to qualitative and quantitative alterations in platelets, neutrophils, complement, and contact systems. Despite the fact that cardiopulmonary bypass is carried out in the presence of high doses of heparin, there is significant activation of both platelets and neutrophils. Thrombin is protected on cell and fibrin surfaces from antithrombin, even in the presence of high doses of heparin (~ 5 U/ml). We therefore studied the effect of a small (Mr = 497), highly effective (Ki = 41 pM), reversible tripeptide inhibitor of thrombin, DUP 714 (1 μM), in a well characterized model of simulated extracorporeal circulation. In the absence of DUP 714, platelet counts decreased by 75% 5 min after the start of extra-corporeal bypass and increased to 48% at 120 min of recirculation. DUP 714 significantly preserved platelet counts, decreased plasma levels of platelet β-thromboglobulin levels, but did not prevent a decrease in sensitivity of platelets to adenosine diphosphate. Kallikrein-C1-inhibitor and C1-C1-inhibitor complexes increased progressively from 0.32 U/ml to 0.67 U/ml and from 4.45 U/ml to 7.25 U/ml, respectively, during 120 min of recirculation without DUP 714. Addition of DUP 714 significantly inhibited kallikrein-C1-inhibitor complex formation but did not affect C1-C1-inhibitor complexes. In the absence of DUP 714, human neutrophil elastase levels rose from a baseline of 0.01 ± 0.00 μg/ml to 1.18 ± 0.21 μg/ml during 120 min of recirculation. Human neutrophil elastase release at 120 min was significantly inhibited in the presence of DUP 714 to 37% of the value with heparin alone. These results indicated that addition of this novel thrombin (and kallikrein) inhibitor to heparin preserved platelet counts, decreased platelet secretion, and provided the additional benefit of partially blocking neutrophil activation during simulated extra-corporeal circulation.

This work was presented in part at the American Society of Hematology Meetings, Nashville, TN, December 2-6, 1994 and published in abstract form in Blood 84: 72a, 1994.

 

  • References

  • 1 Harker LA, Malpass TW, Branson HE, Hessel EA, Slichter SJ. Mechanism of abnormal bleeding in patients undergoing cardiopulmonary bypass: acquired transient platelet dysfunction associated with selective alpha-granule release. Blood 1980; 56: 824-34.
    PubMedGoogle Scholar
  • 2 Neville WE, Kontaxis A, Gavin T, Clowes GH. Postperfusion pulmonary vasculitis. Arch Surg 1963; 86: 126-30.
    CrossrefPubMedGoogle Scholar
  • 3 Ratliff NB, Young WG, Hackel DB, Mikat E, Wilson JW. Pulmonary injury secondary to extracorporeal circulation. J Thorac Cardiovasc Surg 1973; 65: 425-30.
    PubMedGoogle Scholar
  • 4 Edmunds Jr. LH, Ellison N, Colman RW, Niewiarowski S, Rao AK, Addonizio Jr. VP, Stephenson LW, Edie RN. Platelet function during cardiac operation: comparison of membrane and bubble oxygenators. J Thorac Cardiovasc Surg 1982; 83: 805-12.
    PubMedGoogle Scholar
  • 5 Hennessy Jr. VL, Hicks RE, Niewiarowski S, Edmunds Jr. LH, Colman RW. Function of human platelets during extracorporeal circulation. Am J Physiol 1977; 232: H622-H8.
    PubMedGoogle Scholar
  • 6 Dutton RC, Edmunds Jr. LH, Hutchinson JC, Roe BB. Platelet aggregate emboli produced in patients during cardiopulmonary bypass with membrane and bubble oxygenators and blood filters. J Thorac Cardiovasc Surg 1974; 67: 258-65.
    PubMedGoogle Scholar
  • 7 Wachtfogel YT, Musial J, Jenkin B, Niewiarowski S, Edmunds Jr. LH, Colman RW. Loss of platelet alpha 2-adrenergic receptors during simulated extracorporeal circulation: prevention with prostaglandin E1. J Lab Clin Med 1985; 105: 601-7.
    PubMedGoogle Scholar
  • 8 Musial J, Niewiarowski S, Hershock D, Morinelli TA, Colman RW, Edmunds Jr. LH. Loss of fibrinogen receptors from the platelet surface during simulated extracorporeal circulation. J Lab Clin Med 1985; 105: 514-22.
    PubMedGoogle Scholar
  • 9 Davies GC, Sobel M, Salzman EW. Elevated plasma fibrinopeptide A and thromboxane B2 levels during cardiopulmonary bypass. Circulation 1980; 61: 808-14.
    CrossrefPubMedGoogle Scholar
  • 10 Beurling-Harbury C, Galvan CA. Acquired decrease in platelet secretory ADP associated with increased postoperative bleeding in post-cardiopulmonary bypass patients and in patients with severe valvular heart disease. Blood 1978; 52: 13-23.
    PubMedGoogle Scholar
  • 11 Gnanadurai TV, Branthwaite MA, Colbeck JF, Welman E. Lysosomal enzyme release during cardiopulmonary bypass. Anaesthesia 1977; 32: 743-8.
    CrossrefPubMedGoogle Scholar
  • 12 Wachtfogel YT, Kucich U, Greenplate J, Gluszko P, Abrams W, Weinbaum G, Wenger RK, Rucinski B, Niewiarowski S, Edmunds LH, Colman RW. Human neutrophil degranulation during extracorporeal circulation. Blood 1987; 69: 324-30.
    PubMedGoogle Scholar
  • 13 Bolanowski PJ, Bauer J, Machiedo G, Neville WE. Prostaglandin influence on pulmonary intravascular leukocytic aggregation during cardiopulmo-nary bypass. J Thorac Cardiovasc Surg 1977; 73: 221-4.
    PubMedGoogle Scholar
  • 14 Schapira M, Despland E, Scott CF, Boxer LA, Colman RW. Purified human plasma kallikrein aggregates human blood neutrophils. J Clin Invest 1982; 69: 1199-202.
    CrossrefPubMedGoogle Scholar
  • 15 Wachtfogel YT, Kucich U, James HL, Scott CF, Schapira M, Zimmerman M, Cohen AB, Colman RW. Human plasma kallikrein releases neutrophil elastase during blood coagulation. J Clin Invest 1983; 72: 1672-7.
    CrossrefPubMedGoogle Scholar
  • 16 Colman RW, Wachtfogel YT, Kucich U, Weinbaum G, Hahn S, Pixley RA, Scott CF, DeAgostini A, Burger D, Schapira M. Effect of cleavage of the heavy chain of human plasma kallikrein on its functional properties. Blood 1985; 65: 311-8.
    PubMedGoogle Scholar
  • 17 Stancikova M, Rybak M, Simonianova K, Ondrsik M. Influence of human plasma kallikrein on lysosomal enzyme release from polymorphonuclear leukocytes. Agents Actions 1991; 32: 209-12.
    CrossrefPubMedGoogle Scholar
  • 18 Wachtfogel YT, Pixley RA, Kucich U, Abrams W, Weinbaum G, Schapira M, Colman RW. Purified plasma factor XIIa aggregates human neutrophils and causes degranulation. Blood 1986; 67: 1731-7.
    PubMedGoogle Scholar
  • 19 Goldstein IM, Weissmann G. Generation of C5-derived lysosomal enzyme-releasing activity (C5a) by lysates of leukocyte lysosomes. J Immunol 1974; 113: 1583-8.
    PubMedGoogle Scholar
  • 20 Craddock PR, Hammerschmidt D, White JG, Dalmosso AP, Jacob HS. Complement (C5-a)-induced granulocyte aggregation in vitro. A possible mechanism of complement-mediated leukostasis and leukopenia. J Clin Invest 1977; 60: 260-4.
    CrossrefPubMedGoogle Scholar
  • 21 Wachtfogel YT, Harpel PC, Edmunds Jr. LH, Colman RW. Formation of C1s-C1-inhibitor, kallikrein-C1-inhibitor, and plasmin-alpha 2-plasmin-inhibitor complexes during cardiopulmonary bypass. Blood 1989; 73: 468-71.
    PubMedGoogle Scholar
  • 22 Wachtfogel YT, Kucich U, Hack CE, Gluszko P, Niewiarowski S, Colman RW, Edmunds Jr. LH. Aprotinin inhibits the contact, neutrophil and platelet activation systems during simulated extracorporeal perfusion. J Thorac Cardiovasc Surg 1993; 106: 1-10.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 23 Wachtfogel YT, Hack CE, Nuijens JH, Kettner C, Reilly TM, Knabb RM, Bischoff R, Tschesche H, Wenzel H, Kucich U, Edmunds Jr. LH, Colman RW. Selective kallikrein inhibitors alter human neutrophil elastase release during extracorporeal circulation. Am J Physiol 1995; 268: H1352-H7.
    PubMedGoogle Scholar
  • 24 Salzman EW, Rosenberg RD, Smith MH, Lindon JN, Favreau L. Effect of heparin and heparin fractions on platelet aggregation. [Review] [65 refs]. J Clin Invest 1980; 65: 64-73.
    CrossrefPubMedGoogle Scholar
  • 25 Makhoul RG, Greenberg CS, McCann RL. Heparin-associated thrombocytopenia and thrombosis: a serious clinical problem and potential solution. J Vasc Surg 1986; 4: 522-8.
    CrossrefPubMedGoogle Scholar
  • 26 Weitz JI, Hudoba M, Massel D, Maraganore J, Hirsh J. Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors. J Clin Invest 1990; 86: 385-91.
    CrossrefPubMedGoogle Scholar
  • 27 Mannucci PM, Boyer C, Wolf M, Tripodi A, Larrieu MJ. Treatment of congenital antithrombin III deficiency with concentrates. Br J Haematol 1982; 50: 531-5.
    CrossrefPubMedGoogle Scholar
  • 28 Gollub S. Heparin rebound in open heart surgery. Surg Gynecol Obstet 1967; 124: 337-46.
    PubMedGoogle Scholar
  • 29 Nordstrom L, Fletcher R, Pavek K. Shock of anaphylactoid type induced by protamine: a continuous cardiorespiratory record. Acta Anaesthesiol Scand 1978; 22: 195-201.
    CrossrefPubMedGoogle Scholar
  • 30 Frater RW, Oka Y, Hong Y, Tsubo T, Loubser PG, Masone R. Protamine-induced circulatory changes. J Thorac Cardiovasc Surg 1984; 87: 687-92.
    PubMedGoogle Scholar
  • 31 Horrow JC. Protamine: a review of its toxicity. [Review] [69 refs]. Anesth Analg 1985; 64: 348-61.
    PubMedGoogle Scholar
  • 32 Makhoul RG, McCann RL, Austin EH, Greenberg CS, Lowe JE. Management of patients with heparin-associated thrombocytopenia and thrombosis requiring cardiac surgery. Ann Thorac Surg 1987; 43: 617-21.
    CrossrefPubMedGoogle Scholar
  • 33 Chomiak PN, Walenga JM, Koza MJ, Reilly TM, Turlapathy P, Pifarre R. Investigation of a thrombin inhibitor peptide as an alternative to heparin in cardiopulmonary bypass surgery [see comments]. Circulation 1993; 88: II407-II12.
    PubMedGoogle Scholar
  • 34 Kettner C, Mersinger L, Knabb R. The selective inhibition of thrombin by peptides of boroarginine. J Biol Chem 1990; 265: 18289-97.
    PubMedGoogle Scholar
  • 35 Lim MS, Johnston ER, Kettner CA. The solution conformation of (D)Phe-Pro-containing peptides: implications on the activity of Ac-(D)Phe-Pro-boroArg-OH, a potent thrombin inhibitor. J Med Chem 1993; 36: 1831-8.
    CrossrefPubMedGoogle Scholar
  • 36 DeAnda Jr. A, Coutre SE, Moon MR, Vial CM, Griffin LC, Law VS, Komeda M, Leung LL, Miller DC. Pilot study of the efficacy of a thrombin inhibitor for use during cardiopulmonary bypass. Ann Thorac Surg 1994; 58: 344-50.
    CrossrefPubMedGoogle Scholar
  • 37 Knabb RM, Kettner CA, Timmermans PB, Reilly T. In vivo characterization of a new synthetic thrombin inhibitor. Thromb Haemost 1992; 67: 56-60.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 38 Brecher G, Cronkite EP. Morphology and enumeration of human blood platelets. J Appl Physiol 1950; 3: 365-70.
    CrossrefPubMedGoogle Scholar
  • 39 Wintrobe MH. Principles and techniques of blood examination. In: Clinical Hematology. Philadelphia: Lea & Febiger; 1967: 410.
    Google Scholar
  • 40 Born GV. Aggregation of blood platelets by adenosine diphosphate and its reversal. Nature 1962; 194: 927-30.
    PubMedGoogle Scholar
  • 41 Rucinski B, Niewiarowski S, James P, Walz DA, Budzynski AZ. Anti-heparin proteins secreted by platelets: Purification, characterization and radioimmunoassay. Blood 1979; 53: 47-50.
    PubMedGoogle Scholar
  • 42 Hack CE, Hannema AJ, Eerenberg Belmer AJ, Out TA, Aalberse RC. A C1-inhibitor-complex assay (INCA): a method to detect C1 activation in vitro and in vivo. J Immunol 1981; 127: 1450-3.
    PubMedGoogle Scholar
  • 43 Nuijens JH, Huijbregts CC, Eerenberg Belmer AJ, Abbink JJ, Strack van Schijndel RJ, Felt Bersma RJ, Thijs LG, Hack CE. Quantification of plasma factor XIIa-Cl(-)-inhibitor and kallikrein-Cl(-)-inhibitor complexes in sepsis. Blood 1988; 72: 1841-8.
    PubMedGoogle Scholar
  • 43a Winer BJ, Brown DR, Michels KM. Statistical Principles in Experimental Design. 3rd ed. New York: McGraw-Hill; 1991. p 497.
    Google Scholar
  • 43b Greenhouse SW, Geisser S. On methods in the analysis of profile data. Psychometrika 1959; 24: 95-112.
    CrossrefPubMedGoogle Scholar
  • 44 Mann KG. Prothrombin and thrombin. In: Hemostasis and Thrombosis: Basic Principles and Clinical Practice. Colman RW, Hirsh J, Marder VJ, Salzman EW, eds. Philadelphia: J. B. Lippincott; 1993. p 184.
    Google Scholar
  • 45 Blombäck B. The N-terminal disulphide knot of human fibrinogen. Br J Haematol 1969; 17: 145-57.
    CrossrefPubMedGoogle Scholar
  • 46 Vu TK, Hung DT, Wheaton VI, Coughlin SR. Molecular cloning of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor activation. Cell 1991; 64: 1057-68.
    CrossrefPubMedGoogle Scholar
  • 47 Weksler BB, Ley CW, Jaffe EA. Stimulation of endothelial cell prostacyclin production by thrombin, trypsin, and the ionophore A 23187. J Clin Invest 1978; 62: 923-30.
    CrossrefPubMedGoogle Scholar
  • 48 Bar-Shavit R, Kahn A, Fenton JW, Wilner GD. Chemotactic response of monocytes to thrombin. J Cell Biol 1983; 96: 282-5.
    CrossrefPubMedGoogle Scholar
  • 49 Bizios R, Lai L, Fenton JW, Malik AB. Thrombin-induced chemotaxis and aggregation of neutrophils. J Cell Physiol 1986; 128: 485-90.
    CrossrefPubMedGoogle Scholar
  • 50 Rinder CS, Rinder HM, Smith BR, Fitch JC, Smith MJ, Tracey JB, Matis LA, Squinto SP, Rollins SA. Blockade of C5a and C5b-9 generation inhibits leukocyte and platelet activation during extracorporeal circulation. J Clin Invest 1995; 96: 1564-72.
    CrossrefPubMedGoogle Scholar
  • 51 Sundaram S, Gikakis N, Hack E, Niewiarowski S, Edmunds LH, Rao AK, Sun L, Cooper SL, Colman RW. Nafamostat mesilate, a broad spectrum protease inhibitor, modulates platelet, neutrophil and contact activation in simulated extracorporeal circulation. Thromb Haemost 1996; 75: 76-82.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 52 Gaarder A, Jonsen J, Laland S, Hellem A, Owren PA. Adenosine diphosphate in red cells as a factor in the adhesiveness of human blood platelets. Nature 1961; 192: 531-40.
    CrossrefPubMedGoogle Scholar
  • 53 Addonizio VP, Smith JB, Strauss III JF, Colman RW, Edmunds Jr. LH. Thromboxane synthesis and platelet secretion during cardiopulmonary bypass with bubble oxygenator. J Thorac Cardiovasc Surg 1980; 79: 91-6.
    PubMedGoogle Scholar
  • 54 Downing SW, Edmunds Jr. LH. Release of vasoactive substances during cardiopulmonary bypass. Ann Thorac Surg 1992; 54: 1236-40.
    CrossrefPubMedGoogle Scholar